Stephen Robertson
Vermögen: 9 Mio $ am 31.07.2026
Vermögen: 9 Mio $ am 31.07.2026
Stephen P.
Robertson is Secretary, Chief Legal & Compliance Officer at Kezar Life Sciences, Inc. since 2026.
Mr. Robertson is Secretary, Chief Legal Officer & Chief Compliance at Aurinia Pharmaceuticals, Inc. since 2014.
Formerly, Mr. Robertson was a Partner at Borden Ladner Gervais LLP from 2014 to 2020.
Education includes graduate studies at the University of Manitoba and undergraduate studies at Simon Fraser University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.08.2026 | 600.787 ( 0,47 % ) | 9 Mio $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| AURINIA PHARMACEUTICALS INC. | Compliance Officer | 02.11.2020 |
| KEZAR LIFE SCIENCES, INC. | Compliance Officer | 11.05.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
Borden Ladner Gervais LLP
Borden Ladner Gervais LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01.01.2020 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Borden Ladner Gervais LLP
Borden Ladner Gervais LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Simon Fraser University
Simon Fraser University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Manitoba
University of Manitoba Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aurinia Pharmaceuticals, Inc.
Aurinia Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics | Health Technology |
Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. BiotechnologyHealth Technology Discovers and develops therapies targeting protein homeostasis | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen